ReviewCurrent drug targets2013
Serum S100B represents a new biomarker for mood disorders.
Review in Current drug targets, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05646160 (Effects of Myofascial Trigger Points Therapy in Migraine.), which is not on this map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Myofascial Trigger Points Therapy in Migraine.
Who cites it
48 citing papers in PubMed, 114 citations in OpenAlex.
- Serum levels of S100B in patients with chronic schizophrenia during treatment augmentation with sarcosine: results of the double-blind, randomized, placebo-controlled PULSAR study.Frontiers in pharmacology · 2026Trial
- S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression.The international journal of neuropsychopharmacology · 2015Trial
- Peripheral biomarkers associated with apathy and predicting response to methylphenidate: Secondary analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET2) study.International psychogeriatrics · 2026Article
- Are S100B and VILIP-1 Involved in a Common Mechanism of Neuroinflammation in Major Depressive Disorder?The Psychiatric quarterly · 2025Article
- Elevated neuron specific enolase levels in post-traumatic stress disorder.European journal of pediatrics · 2024Article
- Changes in S100 calcium-binding protein β (S100β) and cognitive function from pre- to post-chemotherapy among women with breast cancer.Brain, behavior, & immunity - health · 2024Article
- Caregiving-Related Depression Increases Neuroinflammation in Spousal Caregivers to Individuals With Cognitive Impairment: A Longitudinal Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Inflammatory mediators in major depression and bipolar disorder.Translational psychiatry · 2024Review
- Gender differences in plasma S100B levels of patients with major depressive disorder.BMC psychiatry · 2024Article
- Biological Markers in Newly Diagnosed Generalized Anxiety Disorder Patients: 8-OHdG, S100B and Oxidative Stress.Neuropsychiatric disease and treatment · 2024Article
- The beneficial effects of vortioxetine on BDNF, CREB, S100B, β amyloid, and glutamate NR2b receptors in chronic unpredictable mild stress model of depression.Psychopharmacology · 2023Article
- Astroglial Connexin 43-Mediated Gap Junctions and Hemichannels: Potential Antidepressant Mechanisms and the Link to Neuroinflammation.Cellular and molecular neurobiology · 2023Review
- Metabolic Syndrome and Adipokines Profile in Bipolar Depression.Nutrients · 2023Article
- Blood-brain barrier permeability and electroconvulsive therapy: a systematic review.Acta neuropsychiatrica · 2023Review
- Serum Levels of S100B Protein and Myelin Basic Protein as a Potential Biomarkers of Recurrent Depressive Disorders.Journal of personalized medicine · 2023Article
- Peripheral S100B Protein Levels in Five Major Psychiatric Disorders: A Systematic Review.Brain sciences · 2023Review
- Review
- Circulating S100B levels at birth and risk of six major neuropsychiatric or neurological disorders: a two-sample Mendelian Randomization Study.Translational psychiatry · 2023Article
- Blood-Brain Barrier Dysfunction in the Pathogenesis of Major Depressive Disorder.Cellular and molecular neurobiology · 2022Review
- Intracellular Protein S-Nitrosylation-A Cells Response to Extracellular S100B and RAGE Receptor.Biomolecules · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, mood disorders have been discussed to be characterized by glial pathology. The protein S100B, a growth and differentiation factor, is located in, and may actively be released by astro- and oligodendrocytes. This protein is easily assessed in human serum and provides a useful parameter for glial activation or injury. Here, we review studies investigating the glial marker S100B in serum of patients with mood disorders. Studies consistently show that S100B is elevated in mood disorders; more strongly in major depressive than bipolar disorder. Consistent with the glial hypothesis of mood disorders, serum S100B levels interact with age with higher levels in elderly depressed subjects. Successful antidepressive treatment has been associated with serum S100B reduction in major depression, whereas there is no evidence of treatment effects in mania. In contrast to the glial marker S100B, the neuronal marker protein neuron-specific enolase is unaltered in mood disorders. Recently, serum S100B has been linked to specific imaging parameters in the human white matter suggesting a role for S100B as an oligodendrocytic marker protein. In sum, serum S100B can be regarded as a promising in vivo biomarker for mood disorders deepening the understanding of the pathogenesis and plasticity-changes in these disorders. Future longitudinal studies combining serum S100B with other cell-specific serum parameters and multimodal imaging are warranted to further explore this serum protein in the development, monitoring and treatment of mood disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.